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Abstract
Background: Patients co-infected with hepatitis B virus (HBV) and the human immunodeficiency virus (HIV) are at
risk of developing hepatocellular carcinoma (HCC). In sub-Saharan Africa, the overlap between high HIV and HBV
prevalence may increase the incidence of HCC. This study investigated the impact of HBV/HIV co-infection on age
at presentation and survival of HCC.
Methods: Ethical approval was obtained to recruit, following informed written consent, patients diagnosed with
HCC at oncology units at four South African hospitals. Between December 2012 and August 2015, patients newly
diagnosed with HCC were recruited and provided demographic and clinical data and blood specimens. Patients
were tested for HBV, hepatitis C virus (HCV) and HIV. Survival data was available for a subset of patients.
Results: Of 107 HCC cases, 83 (78%) were male. Median age was 46 years (range 18 to 90 years), 68/106 (64%) were
HBsAg-positive, and 22/100 (22%) were HIV infected. Among HBV surface antigen (HBsAg)-positive HCC cases, 18/66
(27%) were HIV-infected compared to 3/34 (9%) among those that were HBsAg-negative (p = 0.04). A greater
proportion of HBV/HIV co-infected cases were female than HBV mono-infected (6/18, 33% vs 6/47, 13%; p = 0.005).
In addition, HBV/HIV co-infected females presented at a younger mean age (36.8 years) than HBV mono-infected
women (50.5 years) (p = 0.09). Median survival was 82 days among the HIV-infected HCC patients compared to 181
days among those without HIV (p = 0.15).
Conclusions: HCC is an important complication in the HIV/HBV infected patient. HIV-positive patients presented
with HCC at a younger age than HIV-negative patients, this effect appears to be greater in women. These data
provide more evidence supporting the call to address. HCC as a cause of morbidity and mortality in the HBV/HIV
co-infected patient population. (281 words).
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Background
Hepatocellular carcinoma (HCC) is the second most
common cause of cancer mortality worldwide [1]. Sub-
Saharan Africa (SSA) has the second highest number of
HCC cases worldwide after South East Asia [2]. It is esti-
mated that 60% of all HCC cases in developing countries
are due to chronic HBV infection (CHB) [3]. This is des-
pite the availability of a safe and effective vaccine for
over three decades.
HCC in African populations appears to affect men
more commonly than women [4]. Patients tend to
present very late with malignancy and time to death
post-diagnosis is short. The data from previous studies
suggests that the average survival time from the onset of
symptoms is around 11–12 weeks and 6–7 weeks from
the time of diagnosis [5, 6], with less than 10% of pa-
tients surviving beyond a year after diagnosis [7].
CHB has an intermediate to high prevalence (5–7%)
among adults in southern SSA [8], although studies sug-
gest the prevalence in South Africa is lower than this at
around 2–3% [9, 10]. SSA has the highest number of
people living with human immunodeficiency virus (HIV)
infection [11]. HIV as a risk factor for the development
of cancer was first recognized because of its strong asso-
ciation with other virally driven malignancies, such as
Kaposi’s sarcoma secondary to human herpes virus-8
(HHV8) infection, and non-Hodgkin’s lymphoma with
Epstein-Barr virus (EBV) infection. These cancers usually
develop in patients with untreated HIV infection [12, 13]
and are now declining because of combined antiretro-
viral therapy (ART) [14]. However, the improved longev-
ity in treated HIV infection has increased the incidence
of other serious non-AIDS-related malignancies, includ-
ing HCC [15–17].
Little is known about the natural history of HCC in
the HBV/HIV co-infected patient. In fact, the question
of whether HIV increases the risk of HCC in patients
with CHB still remains largely unanswered. Two studies
from resource rich settings suggest that HIV may hasten
the evolution of HBV-related HCC, resulting in an earl-
ier age of presentation in the HIV co-infected patient
[18, 19]. These data were confirmed in a small West Af-
rican study of 60 HCC patients in which seven HIV-
infected cases presented at a younger median age of 32
years [interquartile range: 31–44] compared to 49 years
[interquartile range; 44–59] among 53 patients without
HIV infection [13]. A case-control study conducted
within the Swiss HIV Cohort Study reported that de-
creased CD4+ cell counts were associated with an in-
creased risk of HCC development among HIV-infected
patients who were co-infected with HBV [20]. However,
a recent case-control study in South Africa did not find
an increased risk for HCC in HIV-infected individuals
[21]. Little is known about HCC in the HIV/HBV
infected African patient. The aim of this study was to
describe the natural history of HCC in an HBV/HIV co-
infected and monoinfected population.
Methods and materials
Study population
Between December 2012 and August 2015, patients who
were newly diagnosed with primary HCC were prospect-
ively recruited into the study from oncology departments
at four university teaching hospitals in South Africa:
Tygerberg Hospital and Groote Schuur Hospital in the
Western Cape Province and Chris Hani-Baragwanath
Academic Hospital and Charlotte Maxeke Johannesburg
Academic Hospital in Gauteng Province. The diagnosis
of HCC was based on radiological examination by
contrast-enhanced computed tomography, abdominal
ultrasound scan and/or magnetic resonance imaging and
clinical findings. An experienced oncologist reviewed all
patients. A subset of 25 cases also had histologic diagno-
sis of HCC. Serum alpha-fetoprotein (AFP) was mea-
sured, but levels < 400 μg/L did not exclude diagnosis of
HCC. Following consent patients were interviewed using
a standardized questionnaire, had a physical examination
and provided blood samples. Clinical laboratory data
were extracted from clinical records. A sub-group of the
patients recruited from the Western Cape, underwent
follow up for survival analysis. This was achieved by
means of following up cases via the South African De-
partment of Home Affairs to determine date of death
(where applicable) using the national identification
number.
Ethical considerations
All participants were recruited following written in-
formed consent according to the Declaration of Helsinki
2008. Ethical approval for the study was obtained from
the health research ethics committees at Universities of
Stellenbosch, Cape Town and Witwatersrand.
Laboratory testing
Blood specimens were collected in EDTA anticoagulant
and SST tubes with silica clot activator upon enrolment
into the study. The tubes were centrifuged to separate
plasma or serum and stored at − 80 °C until they were
used for serologic and molecular testing. The HBsAg
test was performed using the DiaSorin Murex HBsAg
Version 3 immunoassay kit (DiaSorin, Saluggia, Italy).
HBeAg and antibodies to HBeAg (anti-HBe) were tested
using the ETI-EBK PLUS and ETI-AB-EBK PLUS (Dia-
Sorin), respectively. Total antibodies against HBV core
antigen (anti-HBc) were measured using the Murex
Anti-HBc (total) immunoassay kit (DiaSorin). Antibodies
to HCV and HIV were tested on the Abbott Architect
i2000SR immunoanalyzer (Abbott Laboratories, Abbott
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Park, Illinois, USA). HBV DNA quantification and geno-
typing were performed as previously described on
HBsAg-positive samples [22, 23]. HBV genotypes were
obtained using the online genotyping databases of Stan-
ford University, the Max Planck Institute for Informatics
and the National Library of Medicine HBV genotyping
tool. HCV viral load was tested using the COBAS
AmpliPrep/COBAS TaqMan HCV assay.
Statistical testing
All data entry and storage were performed in Epi-Info 7
(Centres for Disease Control, GA, USA) and statistical
analysis was carried out in Statistica version 12 (StatSoft,
Oklahoma, USA). Non-parametric data or small-sample
data were described using medians and interquartile
ranges and compared using the Mann-Whitney test
where there were only two groups or the Kruskal-Wallis
test in cases of three or more groups. Data with normal
distribution were described using means and 95% confi-
dence intervals. Comparisons were performed using the
unpaired t-test where data were normally distributed.
Categorical data were described using proportions and
analysed using the chi-square test or Fisher’s exact test,
depending on the number of observations. Survival after
diagnosis of HCC was evaluated using the Kaplan-Meier
method, and comparisons between patients infected and
uninfected with HIV were performed with the log-rank
test. Graphs were constructed using GraphPad Prism
version 5 (GraphPad Software, CA, USA). All hypothesis
testing was done at 95% confidence intervals and results
were regarded as significant if p < 0.05.
Results
Demographic and clinical characteristics
A total of 107 HCC patients were recruited between De-
cember 2012 and August 2015. The mean age was 46
years (95% CI: 43–49), range 18–90 years. The majority
were male 78% (83/107) and 55% (59/107) were Black
African. Twenty two percent (22/100) of cases were HIV
infected, of whom 91% (20/22) had evidence of current
or past HBV infection. There was insufficient specimen
for HIV testing for seven cases. Table 1 shows the
demographic and clinical characteristics of the 100 pa-
tients with known HIV status.
The median serum AFP was 6176 μg/L (interquartile
range: 120–47,750). Of 98 cases, 69 (70%) had serum
AFP greater than 400 μg/L. The majority of cases were
diagnosed using imaging modalities in combination with
clinical laboratory data. Contrast-enhanced computed
tomography (CT) scan was done in 77 of 107. Liver
histological examination was done on 31/100 of cases on
whom information was provided (data was missing on
seven cases).
Prevalence of HBV serological markers
Of 106 serum samples tested (one had insufficient vol-
ume for testing), 68 (64.1%, 95% CI: 59–77) were sero-
positive for HBsAg, and 85/103 (82.5, 95% CI: 76–90)
were anti-HBc positive. The mean age of the HBV-
Table 1 Demographic and clinical characteristics of HCC cases
by known HIV status
HIV-infected, N (%) HIV-uninfected, N (%) p-value
22 (22) 78 (78)
Age groups (in years)
18–34 5 (23) 23 (29.5) 0.003
35–49 14 (64) 18 (23)
50–59 2 (9) 23 (29.5)
60–90 1 (5) 14 (18)
Gender
Male 14 (64) 64 (72) 0.03
Female 8 (36) 14 (18)
Race
African 20 (91) 32 (43) 0.0004
Caucasian 0 (0.0) 6 (8)
Mixed 2 (9) 36 (49)
Missing dataa 0 4
Place of birth
Urban 14 (70) 44 (60) 0.4
Rural 6 (30) 29 (40)
Missing dataa 2 5
Alcohol dependence
Yes 5 (24) 15 (21) 0.7
No 16 (76) 57 (79)
Missing dataa 1 6
Known cirrhosis
Yes 5 (25) 15 (22) 0.8
No 15 (75) 52 (78)
Missing dataa 2 11
HBsAg status
Positive 18 (82) 47 (60) 0.06
Negative 4 (18) 31 (40)
Anti-HBc status
Positive 20 (91) 62 (83) 0.5
Negative 2 (9) 13 (17)
Missing dataa 0 3
Anti-HCV
Positive 1 (5) 7 (9) 0.7
Negative 20 (95) 68 (91)
Missing dataa 1 3
Missing dataa not included in the statistical analysis
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infected cases was 44 years (95% CI: 41–47) compared to
49 years (95% CI: 43–54) among those HBV-uninfected,
p = 0.16. Among the 34 HBsAg negative samples, 17
(50%, 95% CI: 32–65) were positive for anti-HBc, indi-
cating HBV exposure. Male HBsAg positive patients
were younger (mean age 43.8 years, 95% CI: 40.1–47.5)
than male HBsAg negative patients (mean age 50.4 years,
95% CI: 44.2–56.9), (p = 0.07). However, the HBsAg-
positive female patients were similar in age (45.2 years,
95% CI: 35.8–54.6) to the HBsAg negative females (45.6
years, 95% CI: 32.9–58.2).
Of the 68 HBsAg seropositive patients, 65 were
tested for HBeAg. There was insufficient serum in
three cases. The overall prevalence of HBeAg among
the HBsAg positive cases was 20/65 (31%). Five of 11
female patients (45%, 95% CI: 15–74) were HBeAg-
positive, while only 15 of 54 male patients (28%, 95%
CI: 14–40) were HBeAg positive, p = 0.29.
Association of HBV/HIV co-infection with demographic
and clinical characteristics at presentation of HCC
Table 2 shows the demographic and clinical characteris-
tics of the 100 patients with known HIV status. Of the
22 HIV-infected patients, 14 were receiving cART. Nine
were prescribed tenofovir, lamivudine and efavirenz; one
was on lamivudine, stavudine and nevirapine; for the
remaining four, no data was available. The median
CD4+ T cell count at time of HCC diagnosis was 293
cells/μL (IQR: 200–602).
The mean age of HIV-infected patients at HCC diag-
nosis was 39.7 years (95% CI: 36.0–43.5); that of unin-
fected patients was 46.4 years (95% CI: 42.8–50.0), p =
0.07. The mean age of HIV-infected female patients was
35.8 years (95% CI: 34.1–40.0), 13 years younger than the
mean age of HIV-uninfected females, 48.5 years (95% CI:
37.4–59.6), p = 0.08. The mean age of HIV-infected male
HCC cases was 42.0 years (95% CI: 36.6–47.4), the mean
age of HIV-uninfected males was 45.9 years (95% CI:
42.2–49.8) p = 0.4.
Eighteen of the HIV-infected (81.8%) and 47 (60.3%)
of the uninfected patients had active HBV infection
(HBsAg seropositive) (p = 0.06). The two patients who
were HIV infected and had no evidence of HBV infec-
tion, both had histological confirmation of the diagnosis.
One of the two HIV-infected patients had a history of al-
coholic liver disease as a risk factor.
HBV genotypes were determined for 43 cases, nine
of whom were HBV/HIV co-infected. All nine of the
co-infected patients and 25/34 (74%) of the mono-
infected patients had HBV genotype A. HCC cases in-
fected with HBV genotype A had a median age of 36
years (IQR: 31–48) compared to 53 years (IQR: 50–
58) in those infected with HBV genotype D, p = 0.008.
Prevalence of HCV infection
Antibodies to HCV were detected in 10 of 101 cases
(9.9, 95% CI: 4.1–15.7). There was insufficient sample
for testing in six cases. The mean age of the anti-HCV
positive subjects was 57.5 years (95% CI: 45.8–69.2),
while that of the anti-HCV negative cases was 12 years
younger, 44.6 years (95% CI: 41.8–48.0) p = 0.01. Of the
ten anti-HCV seropositive HCC cases, 9 (90%) were
male. Among the ten anti-HCV positive cases, three
were HBV/HCV co-infected while one case had triple
infection with HCV, HBV and HIV. Of eight anti-HCV
positive cases, 5 (63%) had detectable HCV RNA with a
median of 6.27 log10 copies/ml (IQR: 5.67 log10–6.42
log10). Samples from four HCV-infected HCC cases
were successfully sequenced - two cases were infected
with HCV genotype 5a while one case each had geno-
type 1a and the other genotype 1b.
Survival of HCC patients
Of the 22 HIV-infected HCC patients, 15 (68.2%) died
during follow up, while of the 78 patients without HIV,
44 (56.4%) died during follow-up. The Kaplan-Meier
survival curves of the two groups were not significantly
different, p = 0.15. The survival curves of the HCC cases
with and without HIV infection are shown in Fig. 1. Me-
dian survival was 82 days among the HIV-infected pa-
tients and 181 days among those without HIV.
Discussion
Primary liver cancer accounts for 600,000 deaths each
year [24]. HCC is the most common primary liver can-
cer, accounting for over 90% of all cases [25]. Vaccin-
ation has been shown to reduce the incidence of HBV-
related liver cancer. However, the hepatitis B vaccine
was not introduced into South Africa’s Expanded
Programme on Immunisation until 1996. Prior to that
time, childhood-acquired HBV infections were common
in much of Africa. All the HCC patients recruited into
this study were born before 1996.
The prevalence of HIV among HCC patients in this
study was 22% (95% CI: 14–30), higher than the preva-
lence of HIV in the South African adult population, esti-
mated at 14.4% among females and 9.9% among males
from the 2012 South African National HIV Prevalence,
Incidence and Behaviour Survey Report [26]. Moreover,
the prevalence was particularly high among females in
this study; 36% of whom were HIV-infected. The major-
ity of HIV/HBV co-infected women were African Blacks,
evidence of the vulnerability of this group to HIV infec-
tion within sub-Saharan Africa [27, 28]. HIV/HBV co-
infected females were about 10 years younger at HCC
diagnosis than HBV mono-infected females, although
the difference did not reach statistical significance. Our
observations are consistent with those of a few African
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Table 2 Demographic and clinical characteristics according to known HIV and HBsAg status
HIV+ HBV+ HIV- HBV+ HIV+ HBV- HIV- HBV-
18 (18%) 47 (47%) 4 (4%) 31 (31%) p-value
Age groups (in years)
18–34 4 (22) 15 (32) 1 (25) 8 (26)
35–49 12 (67) 13 (28) 2 (50) 5 (16) 0.04
50–59 1 (5.5) 11 (23) 1 (25) 12 (39)
60–90 1 (5.5) 8 (17) 0 (0) 6 (19)
Gender
Male 12 (67) 41 (87) 2 (50) 23 (74) 0.1
Female 6 (33) 6 (13) 2 (50) 8 (26)
Ethnicity
Black African 16 (89) 23 (50) 4 (100) 9 (32) 0.006
Caucasian 0 (0) 3 (7) 0 (0) 3 (11)
Mixed ancestry 2 (11) 20 (43) 0 (0) 16 (57)
Missing data 0 1 0 3
Alcohol dependence
Yes 4 (22) 8 (18) 1 (3) 7 (25) 0.9
No 14 (78) 36 (82) 2 (67) 21 (75)
Missing data 0 3 1 0
Known cirrhosis
Yes 5 (29) 12 (27) 0 (0) 3 (13) 0.4
No 12 (71) 32 (73) 3 (100) 20 (87)
Missing data 1 3 1 5
HBeAg positive
Yes 10 (59) 9 (20) n/a n/a 0.003
No 7 (41) 37 (80)
Missing data 1 1
HBV genotypes
A 9 (100) 25 (76) n/a n/a 0.00009
D 0 (0) 7 (21)
E 0 (0) 1 (3)
AFP > 400 μg/L
Yes 11 (61) 35 (80) 3 (75) 14 (54) 0.1
No 7 (39) 9 (20) 1 (25) 12 (46)
Missing data 0 3 0 5
Child-Pugh
A 9 (60) 30 (68) 2 (67) 14 (59) 1.0
B 5 (33) 11 (25) 1 (33) 8 (33)
C 1 (7) 3 (7) 0 (0) 2 (8)
Missing data 3 3 1 7
Nodules at diagnosis
Single lesion < 2 cm 3 (19) 5 (12) 0 (0) 4 (14)
Single lesion 2–5 cm 0 (0) 0 (0) 0 (0) 1 (4) 1.0
Single lesion > 5 cm 2 (12) 6 (14) 0 (0) 4 (14)
Multiple lesions 11 (69) 31 (74) 1 (100) 19 (68)
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studies that have evaluated the effect of HIV on the epi-
demiology of HCC in Africa [13]. These studies have re-
ported that HIV-infected liver cancer patients were 10
years younger at diagnosis than patients without HIV.
The patients with HBV infection were younger at
HCC diagnosis than those that were infected with HCV
in this study. This finding is consistent with reports that
HCV-associated HCC tends to peak in the sixth decade
of life and HBV-associated HCC in the fourth decade
[29]. The differences in age at presentation probably re-
flect the ages of acquisition of viral hepatitis infection
and the differing oncogenic processes of these two vi-
ruses. In sub-Saharan Africa, HBV infection is predom-
inantly acquired early in childhood through vertical and
horizontal transmission, while HCV is acquired, pre-
dominantly in high-risk groups, in adulthood. HCV asso-
ciated HCC is more often associated with cirrhosis than
HBV associated HCC, and therefore presenting later in
life either in the context of liver cirrhosis.
We found that patients who were infected with HBV
genotype A presented at a significantly younger age than
those with genotype D. That finding is consistent with
that of Kew et al., who described a mean age difference
of almost 7 years [30]. The frequent absence of HBeAg
and the basal core promotor mutations in genotype D
compared to genotype A may provide an explanation for
the difference in age at presentation between the two ge-
notypes. HBeAg positivity, which normally denotes high
HBV replication, is a known risk factor for HCC devel-
opment and tends to be more prevalent, together with
the basal core promoter mutations, in patients infected
with genotype A compared to those with D [31].
Fifty-five percent of HCC patients in this study
were Black Africans who are thought to be at higher
risk of HCC than other racial groups due to greater
exposure to factors predisposing to HCC, such as
dietary iron overload and HBV and HIV infection [32,
33]. Cirrhosis prevalence in HBV-associated HCC
among African patients has previously been reported
to be 44–63% [34–36]. However, only 23% of our pa-
tients had known underlying cirrhosis at HCC diag-
nosis, probably because their diagnoses of cirrhosis
were based on clinical rather than histological param-
eters. Clinical assessment of cirrhosis is known to re-
sult in under-diagnosis and under-reporting of its
true prevalence, especially among patients with com-
pensated cirrhosis. Studies from the United States
have also found that cirrhosis was not identified
Table 2 Demographic and clinical characteristics according to known HIV and HBsAg status (Continued)
HIV+ HBV+ HIV- HBV+ HIV+ HBV- HIV- HBV-
18 (18%) 47 (47%) 4 (4%) 31 (31%) p-value
Missing data 2 5 1 3
Missing/unknown data, (including cases with unknown HIV status) are excluded from the table and statistical analysis
Fig. 1 Survival rates according to known HIV status. Comparison between Kaplan–Meier survival curves in 22 HIV-infected patients with HCC and
78 HIV-uninfected HCC patients. Patients whose HIV status was unknown were not included in this survival analysis
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among 24–30% of HCC patients who had underlying
cirrhosis [37, 38]. In patients with hepatitis C, HCC
invariably develops following cirrhosis such that early
diagnosis of malignancy is diminished when cirrhosis
is diagnosed late [38]. However, cirrhosis is not ne-
cessary for the development of HCC in CHB.
Our findings raise questions regarding implementation
of current hepatitis B treatment and HCC screening
guidelines in South Africa. Patients with viral hepatitis
have access to tertiary level treatment and surveillance
programmes but without wider access to screening for
HBV infection, it is not possible to implement them. Un-
fortunately, many HBV infections are only diagnosed
once they present with HCC. Few of our HBV-mono-
infected patients had been screened and treated for CHB
before their HCC diagnosis. As a result, many patients
have radiological findings of multiple or large liver le-
sions at presentation. Only 30% of cases in this current
study had histologic diagnosis of HCC. This has implica-
tions with regard to understanding the true burden of
HCC with South Africa whose national cancer registry is
pathology-based. As a result, there is an underestimation
of the burden of HCC and this impacts on the allocation
of resources towards the health burden.
Among these HCC patients in this study, survival was
dismal regardless of HBV or HIV status. Although the
HIV-infected HCC patients had a median survival of 82
days, compared to 181 days among those without HIV
infection, the difference was not statistically significant.
Nonetheless, the poor survival of HIV-infected patients
compared to HIV-uninfected patients argues against the
probability that the difference in age at diagnosis be-
tween HIV-infected and uninfected HCC patients is due
to lead-time bias. More intense surveillance of HIV-
infected than uninfected patients would be expected to
lead to earlier HCC diagnosis with better prognosis and
survival which was not observed in this study.
An important limitation of this study is recruitment
bias; because we recruited HCC cases only from on-
cology units of state-owned tertiary hospitals, we may
have missed patients presenting with HCC at primary
health care facilities and therefore unable to recruit
all cases. In the setting of a strong health care system,
such patients might be diagnosed earlier and survive
longer. However, anecdotal evidence suggests that
even if patients presented to the primary care facil-
ities with early-stage HCC, those facilities are not
equipped or staffed with appropriately trained individ-
uals to provide early detection and effective treat-
ment. It is more likely that our recruitment approach
missed patients with HCC who did not survive long
enough (after referral to confirm a tentative diagnosis)
to be seen at the recruiting sites for this study. It is
unlikely that HIV and HBV infection would be less
prevalent among such patients than among those in
this cohort.
Our findings suggest that HIV infection may cause
early development of HCC in HBV-infected patients,
particularly in females, and that many patients who
present late with HCC have underlying undiagnosed
and/or untreated HBV infection. Estimates suggest that
only 5% of patients infected with viral hepatitis are aware
of their infection status prior to HCC diagnosis [39].
Most of the HIV-infected patients in our study were
aware of their HIV status. However, very few were aware
of their HBV status.
Conclusions
Our results highlight the need to address the problem of
hepatitis B within sub-Saharan Africa. The majority of
childhood-acquired HBV infections become chronic, and
CHB is the greatest risk factor for HCC in sub-Saharan
Africa. HBV birth dose vaccination is the cornerstone to
the HBV prevention strategy and should be available to
all infants, particularly those born in high prevalence
countries. The South African Ministry of Health takes
the position that it is unnecessary to screen HIV-
infected individuals for HBV because the current first
line ART that includes tenofovir and lamivudine is active
against both HIV and HBV. However, the hypothesis
that ART is sufficient to prevent the evolution of HCC
in HIV-infected patients needs further study. In order to
identify those most at risk of HCC, there is a need to
screen HIV-infected individuals for HBV, to treat those
who test positive for HBV, and to vaccinate those who
are not immune. In addition, better screening and man-
agement strategies for HCC should be developed for
sub-Saharan African populations, where young people,
especially those infected with HIV are at risk of this rap-
idly fatal malignancy.
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